IQVIA report analyzes drug shortages in the U.S.Over the past five-and-a-half years, an average of more than 25 new molecule shortages have occurred annually, with 160 in total added through June of 2023 and only 51 resolved. Eli Lilly gets FDA nod for Zepbound for chronic weight managementThe FDA has approved Eli LIlly's Zepbound for chronic weight management in adults with obesity, in addition to a reduced calorie diet and increased physical activity. Zydus receives FDA OK for Zituvio Zituvio is used to treat adult patients with Type 2 diabetes mellitus. Sun Pharma Canada’s Winlevi rolls out in Canada Winlevi is the first and only topical androgen receptor inhibitor, and the newest Health Canada-approved formulation to target the hormonal component of acne in 40 years. Phathom Pharmaceuticals receives FDA nod for Voquezna Voquezna is a new treatment for adults for the healing and maintenance of all grades of erosive esophagitis. Eli Lilly obtains FDA OK for Omvoh Omvoh is a treatment for adults with moderate to severe ulcerative colitis. Elsevier launches PharmaPendium Elsevier’s PharmaPendium aims to empower pharma companies to bring novel drugs to market faster and increase success of regulatory submissions. GoodRx offers Sanofi’s Lantus for $35 at more than 70,000 pharmacies Americans with a valid prescription, regardless of insurance status, can use GoodRx to access a 30-day supply of Lantus for $35. Santhera receives FDA nod for Agamree Agamree is used to treat Duchenne muscular dystrophy in patients 2 years of age and older. FDA approves new indication for Jardiance Jardinace is now approved for the treatment of adults with chronic kidney disease. First Previous 3 4 5 6 7 Next Last
